Correction to: Schwannoma gene therapy by adeno-associated virus delivery of the pore-forming protein Gasdermin-D.

abstract：:Retroviral replicating vectors (RRVs) have achieved efficient tumor transduction and enhanced therapeutic benefit in a wide variety of cancer models. Here, we evaluated two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which utilize different cellular recept...

journal_title：Cancer gene therapy

authors： Kubo S,Takagi-Kimura M,Kasahara N

更新日期：2019-02-01 00:00:00

abstract：:Oncolytic virotherapy using adenoviruses has potential therapeutic benefits for a variety of cancers. We recently developed MOA5, a tumor-specific midkine promoter-regulated oncolytic vector based on human adenovirus serotype 5 (Ad5). We modified the binding tropism of MOA5 by replacing the cell-binding domain of the ...

journal_title：Cancer gene therapy

authors： Takagi-Kimura M,Yamano T,Tagawa M,Kubo S

更新日期：2014-03-01 00:00:00

abstract：:To develop novel therapies for aggressive thyroid cancers, we have synthesized a collection of histone deacetylase (HDAC) inhibitor analogs named AB1 to AB13, which have different linkers between a metal chelating group and a hydrophobic cap. The purpose of this study was to screen out the most effective compounds and...

journal_title：Cancer gene therapy

authors： Jang S,Yu XM,Odorico S,Clark M,Jaskula-Sztul R,Schienebeck CM,Kupcho KR,Harrison AD,Winston-McPherson GN,Tang W,Chen H

更新日期：2015-08-01 00:00:00

abstract：:Arming oncolytic adenoviral vectors with anticancer transgenes that can be expressed in a tumor-selective manner may enable the engineering of vectors with increased potency, while retaining their safety profile. Armed oncolytic adenoviral vectors were constructed in which transgene expression has been linked via modi...

journal_title：Cancer gene therapy

authors： Robinson M,Ge Y,Ko D,Yendluri S,Laflamme G,Hawkins L,Jooss K

更新日期：2008-01-01 00:00:00

abstract：:Salmonella typhimurium (hereafter S. typhimurium), as Gram-negative facultative anaerobic bacteria, are good candidates for cancer therapy and delivering therapeutic antitumor agents. However, it is necessary to reduce the virulence of such bacteria and enhance their tumor-targeting ability, and their immunostimulator...

journal_title：Cancer gene therapy

authors： Liang K,Liu Q,Li P,Han Y,Bian X,Tang Y,Kong Q

更新日期：2018-08-01 00:00:00

abstract：:We report that radiation enhances the antitumor efficacy of the oncolytic adenovirus vector VRX-007 in Syrian hamster tumors. We used tumor-specific irradiation of subcutaneous tumors and compared treatment options of radiation alone or combined with VRX-007 and cyclophosphamide (CP). Radiation therapy further augment...

journal_title：Cancer gene therapy

authors： Young BA,Spencer JF,Ying B,Toth K,Wold WS

更新日期：2013-09-01 00:00:00

abstract：:Chemotherapy remains the main tool for the treatment of cancers, but is often hampered by tumor cell resistance. In this context, the transfer of genes able to accentuate the effect of anticancer drugs may constitute a useful approach, as exemplified by inactivation of nuclear factor (NF)-kappa B via direct transfer o...

journal_title：Cancer gene therapy

authors： Cherbonnier C,Déas O,Vassal G,Merlin JL,Haeffner A,Senik A,Charpentier B,Dürrbach A,Bénard J,Hirsch F

更新日期：2002-06-01 00:00:00

abstract：:Cationic liposomes are considered to be safe vectors for gene transfer, but they are less efficient at delivering DNA to cells when compared with retroviral vectors. Cationic liposomes complexed with DNA were targeted to specific cells in vitro by means of monoclonal antibodies (mAbs) or ligands associated with the li...

journal_title：Cancer gene therapy

authors： Kao GY,Change LJ,Allen TM

更新日期：1996-07-01 00:00:00

abstract：:Herpes simplex virus type 1 (HSV-1) is one of the most widely studied viruses for oncolytic virotherapy. In squamous cell carcinoma (SCC) cells, the role of autophagy induced by neurovirulence gene-deficient HSV-1s in programmed cell death has not yet been elucidated. The oncolytic HSV-1 strain RH2, which lacks the γ3...

journal_title：Cancer gene therapy

authors： Furukawa Y,Takasu A,Yura Y

更新日期：2017-09-01 00:00:00

abstract：:MicroRNAs (miRNAs) were discovered more than a decade ago as noncoding, single-stranded small RNAs (approximately 22 nucleotides) that control the timed gene expression pattern in Caenorhabditis elegans life cycle. A number of these evolutionarily conserved, endogenous miRNAs have been shown to regulate mammalian cell...

journal_title：Cancer gene therapy

authors： Tong AW,Nemunaitis J

更新日期：2008-06-01 00:00:00

abstract：:Newcastle disease virus (NDV), an avian paramyxovirus, has a potential oncolytic effect that may be of significance in the treatment of a variety of cancer diseases. An attenuated lentogenic isolate of NDV (HUJ) demonstrated a selective cytopathic effect upon a panel of human and mouse lung tumor cells, as compared to...

journal_title：Cancer gene therapy

authors： Yaacov B,Eliahoo E,Lazar I,Ben-Shlomo M,Greenbaum I,Panet A,Zakay-Rones Z

更新日期：2008-12-01 00:00:00

abstract：:Metastasis is the principal cause of cancer death and occurs through multiple, complex processes. Epithelial to mesenchymal transition (EMT) is an important process during embryonic development and has also been hypothesized to exhibit a significant role in cancer cell invasion and metastasis. MicroRNAs (miRNAs) are a...

journal_title：Cancer gene therapy

authors： Zhang Z,Zhang M,Chen Q,Zhang Q

更新日期：2017-02-01 00:00:00

abstract：:To improve the expression levels of transgenes in malignant hematopoietic cells, we developed a novel adenoviral-alphavirus hybrid vector Ad5/F11p-SFV-GFP that contains a Semliki Forest Virus (SFV) replicon and chimeric fibers of Ad5 and Ad11p. Ad5/F11p-SFV-GFP infected >95% of K562, U937 or Jurkat cells and 23.65% of...

journal_title：Cancer gene therapy

authors： Yang Y,Xiao F,Lu Z,Li Z,Zuo H,Zhang Q,Li Q,Wang H,Wang LS

更新日期：2013-08-01 00:00:00

abstract：:Lung cancer is the most frequently occurring cancer in the world and causes more deaths in the United States than does colon, breast, and prostate cancer combined. Despite advances in treatment modalities including radiation, surgery, and chemotherapy, the overall survival in lung cancer remains low. The cytokine tumo...

journal_title：Cancer gene therapy

authors： Sanlioglu S,Luleci G,Thomas KW

更新日期：2001-11-01 00:00:00

abstract：:Survivin is expressed in most cancers but is undetectable in differentiated adult cells, and plays an important role both in the suppression of apoptosis and mitotic spindle checkpoint; thus it has attracted great interest as a potential drug target. In this study, we investigated the antigene and antiproliferative ef...

journal_title：Cancer gene therapy

authors： Shen C,Buck A,Polat B,Schmid-Kotsas A,Matuschek C,Gross HJ,Bachem M,Reske SN

更新日期：2003-05-01 00:00:00

abstract：:Immune responses to tumor-associated antigens are often dampened by a tumor-induced state of immune anergy. Previous work has attempted to overcome tumor-induced T-cell anergy by the direct injection of vectors carrying the genes encoding one of a variety of cytokines. We hypothesised that the polyclonal stimulation o...

journal_title：Cancer gene therapy

authors： Paul S,Regulier E,Rooke R,Stoeckel F,Geist M,Homann H,Balloul JM,Villeval D,Poitevin Y,Kieny MP,Acres RB

更新日期：2002-05-01 00:00:00

abstract：:Various therapeutic approaches toward killing glioma cells by inducing apoptosis have been developed, but these approaches are often hampered by anti-apoptotic mechanisms. In this study, we attempted to develop a technique that overrides the resistance toward apoptosis in glioma cells. To date, p53- and Fas-mediated a...

journal_title：Cancer gene therapy

authors： Shinoura N,Yoshida Y,Asai A,Kirino T,Hamada H

更新日期：2000-05-01 00:00:00

abstract：:Replication-competent oncolytic herpes simplex viruses (HSV), modified by deletion of certain viral growth genes, can selectively target malignant cells. The viral growth gene gamma(1)34.5 has significant homology to GADD34 (growth arrest and DNA damage protein 34), which promotes cell cycle arrest and DNA repair in r...

journal_title：Cancer gene therapy

authors： Jarnagin WR,Zager JS,Hezel M,Stanziale SF,Adusumilli PS,Gonen M,Ebright MI,Culliford A,Gusani NJ,Fong Y

更新日期：2006-03-01 00:00:00

abstract：:Gene-directed enzyme prodrug therapy (GDEPT) is a promising approach to local management of cancer through targeted chemotherapy. Killing localized tumors by GDEPT in a manner that induces strong antitumor cellular immune responses might improve local management and allow benefit in disseminated cancer. Here we evalua...

journal_title：Cancer gene therapy

authors： Djeha HA,Todryk SM,Pelech S,Wrighton CJ,Irvine AS,Mountain A,Lipinski KS

更新日期：2005-06-01 00:00:00

abstract：:Over the past several years we have obtained considerable evidence indicating that adenoviruses-expressing interferon α (Ad-IFNα) can overcome resistance to the IFNα protein itself. Since cancer cells infected with Ad-IFNα also show high perinuclear cytoplasmic IFNα expression, we were interested in whether endoplasmi...

journal_title：Cancer gene therapy

authors： Yang Z,Zhang XQ,Dinney CN,Benedict WF

更新日期：2011-09-01 00:00:00

abstract：:Current oncolytic viruses exert only limited antitumor activity on their own. There is a need to increase their oncolytic capability. We evaluated the effect of a differentiating reagent, hexamethylene bisacetamide (HMBA), on the antitumor activity of a gamma(1)34.5-deficient herpes simplex virus type 1 (HSV-1) R849 f...

journal_title：Cancer gene therapy

authors： Naito S,Obayashi S,Sumi T,Iwai S,Nakazawa M,Ikuta K,Yura Y

更新日期：2006-08-01 00:00:00

abstract：:Interleukin-10 (IL-10) is a T helper type 2 (Th2) cytokine that suppresses Th1-mediated, cell-mediated immune responses and reciprocally enhances antibody-mediated responses. Previous studies, however, demonstrated that forced expression of the IL-10 gene in tumor cells could unexpectedly produce antitumor effects. We...

journal_title：Cancer gene therapy

authors： Kawamura K,Bahar R,Natsume W,Sakiyama S,Tagawa M

更新日期：2002-01-01 00:00:00

abstract：:Direct intratumoral injection of a lipid/DNA complex encoding an allogeneic major histocompatibility complex (MHC) class I molecule leads to regression of both an immunogenic murine tumor and also melanoma lesions in some patients. We have sought to understand the mechanism(s) for this augmentation of antitumor activi...

journal_title：Cancer gene therapy

authors： Fox BA,Drury M,Hu HM,Cao Z,Huntzicker EG,Qie W,Urba WJ

更新日期：1998-09-01 00:00:00

abstract：:Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tu...

journal_title：Cancer gene therapy

authors： Grandi P,Fernandez J,Szentirmai O,Carter R,Gianni D,Sena-Esteves M,Breakefield XO

更新日期：2010-09-01 00:00:00

abstract：:Previous studies have indicated that the cytokine interleukin (IL)-21 may induce both innate and adaptive immune responses against tumors. The goal of this study was to evaluate a new adoptive immunotherapy strategy that combined lymphocytes from mice immunized with a murine myeloma vaccine secreting murine IL-21 (mIL...

journal_title：Cancer gene therapy

authors： Dou J,Wu Y,Wang J,Zhao F,Chu L,Liu C,Wen P,Hu W,Hu K,He XF,Gu N

更新日期：2010-10-01 00:00:00

abstract：:The effect of local and systemic delivery of the angiostatin gene on human melanoma growth was studied in nude mice. Liposome-coated plasmids carrying the cDNA coding for murine and human angiostatin (CMVang and BSHang) were injected weekly, locally or systemically, in mice transplanted with melanoma cells. The treatm...

journal_title：Cancer gene therapy

authors： Rodolfo M,Catò EM,Soldati S,Ceruti R,Asioli M,Scanziani E,Vezzoni P,Parmiani G,Sacco MG

更新日期：2001-07-01 00:00:00

abstract：:A novel gene, HA117, was discovered in our previous work. Using the pSOS-HUS vector method which we designed at previous study, we screened for small interfering RNAs (siRNAs) that targeted HA117. The pSOS-HUS siRNA screening results were verified and a delivery system was developed that contained a recombinant adenov...

journal_title：Cancer gene therapy

authors： Zheng GH,Luo Q,Jin XQ,Guo YX,Xu YH

更新日期：2011-09-01 00:00:00

abstract：:CD40/CD40 ligand (CD40L) interaction plays an essential role in cell-mediated immune responses. We examined whether expression of CD40L in murine lung carcinoma (A11) cells could produce antitumor effects. The proliferation rate in vitro of A11 cells transfected with the murine CD40L gene (A11/CD40L) was not different...

journal_title：Cancer gene therapy

authors： Tada Y,O-Wang J,Yu L,Shimozato O,Wang YQ,Takiguchi Y,Tatsumi K,Kuriyama T,Takenaga K,Sakiyama S,Tagawa M

更新日期：2003-06-01 00:00:00

abstract：:Although gene therapies using tissue-specific promoters have been reported to be a promising tool for treating cancers, few studies have explored this possibility for uterine cervical cancer. MN/CA9 is a transmembrane glycoprotein that was first identified in the human cervical carcinoma cell line, HeLa. Since MN/CA9 ...

journal_title：Cancer gene therapy

authors： Lim HY,Ahn M,Chung HC,Gardner TA,Kao C,Lee SJ,Kim SJ

更新日期：2004-08-01 00:00:00

abstract：:Neprilysin (neutral endopeptidase, NEP) is a cell surface peptidase whose expression is lost in approximately 50% of prostate cancers (PC). NEP normally functions to inactivate peptides such as bombesin and endothelin-1, and potentiates the effects of the PTEN tumor suppressor via a direct protein-protein interaction....

journal_title：Cancer gene therapy

authors： Horiguchi A,Zheng R,Goodman OB Jr,Shen R,Guan H,Hersh LB,Nanus DM

更新日期：2007-06-01 00:00:00